Andrew Lawrence Gundlach

Title: Andrew Lawrence Gundlach: Innovator in Biologically Active Polypeptides

Introduction

Andrew Lawrence Gundlach is a notable inventor based in Hawthorn, Australia. He has made significant contributions to the field of biochemistry, particularly in the development of biologically active polypeptides. With a total of 2 patents, Gundlach's work focuses on innovative treatments for anxiety and related conditions.

Latest Patents

Gundlach's latest patents include "Single chain relaxin polypeptides" and "Method for treatment of anxiety." The first patent relates to biologically active single chain relaxin polypeptides that comprise a relaxin B chain derived from relaxin-3. These polypeptides are truncated by one or more amino acids at the C-terminus of the relaxin-3 B chain and typically act as antagonists of the RXFP3 receptor. The second patent describes human H3 preprorelaxin, human H3 prorelaxin, and human H3 relaxin, along with analogues that have modified A and/or B chains. It also outlines methods for treating conditions responsive to the administration of H3 relaxin or its analogues.

Career Highlights

Throughout his career, Gundlach has worked with esteemed institutions such as the Howard Florey Institute of Experimental Physiology and Medicine and The University of Queensland. His research has significantly advanced the understanding of relaxin and its potential therapeutic applications.

Collaborations

Gundlach has collaborated with notable colleagues, including Ross Alexander David Bathgate and John Desmond Wade. Their combined expertise has contributed to the success of various research projects and innovations in the field.

Conclusion

Andrew Lawrence Gundlach is a prominent figure in the realm of biochemistry, with a focus on developing innovative treatments for anxiety through his patented inventions. His contributions continue to impact the scientific community and pave the way for future advancements in therapeutic applications.